Sotigalimab

索替利单抗

Report date: 2022/07/19 16:22:54

Base Information

Drug NameSotigalimab
Drug Alias NameAPX-005APX-005MEPI-0050
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSkin MelanomaMicrosatellite InstabilityCarcinoma, Non-Small-Cell Lung +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEpitomics Inc
China Registration ClassN/A

Develop Information

Active CompaniesParker Institute For Cancer ImmunotherapyApexigen IncYale University
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsEsophageal Neoplasms +[5] 
Inactive IndicationsSkin MelanomaMicrosatellite InstabilityCarcinoma, Non-Small-Cell Lung +[8] 

Other Information

ATC CodeN/A
Related LinksN/A